



Microbiota succession throughout life from the cradle to the grave

Cameron Martino^{1,2,3,11}, Amanda Hazel Dilmore^{1,4,11}, Zachary M. Burcham⁵, Jessica L. Metcalf⁶, Dilip Jeste^{3,6,7,8} and Rob Knight^{1,3,9,10}✉

Abstract | Associations between age and the human microbiota are robust and reproducible. The microbial composition at several body sites can predict human chronological age relatively accurately. Although it is largely unknown why specific microorganisms are more abundant at certain ages, human microbiota research has elucidated a series of microbial community transformations that occur between birth and death. In this Review, we explore microbial succession in the healthy human microbiota from the cradle to the grave. We discuss the stages from primary succession at birth, to disruptions by disease or antibiotic use, to microbial expansion at death. We address how these successions differ by body site and by domain (bacteria, fungi or viruses). We also review experimental tools that microbiota researchers use to conduct this work. Finally, we discuss future directions for studying the microbiota's relationship with age, including designing consistent, well-powered, longitudinal studies, performing robust statistical analyses and improving characterization of non-bacterial microorganisms.

Human-associated microbiotas are communities of bacteria, fungi, protists, archaea and viruses (often referred to as the bacteriome, mycobiome, protistome, archaeome and virome, respectively) that live on and/or inside the human body. We know far more about how bacterial communities change across age groups than about fungi, archaea, protists or viruses, but that does not necessarily translate to bacteria being of disproportionate importance. Microbial communities exist on every mucosal surface in the human body, and each body site within a person has a unique ecology^{1–3}. Each individual's human-associated microbial community is unique compared with that of all other humans⁴. Human-resident microorganisms encode an estimated 2 million to 20 million genes, whereas the human genome encodes an estimated 20,000 to 25,000; therefore, the microbiome represents up to 99.9% of the genetic capacity in the human body⁵. During each stage of life from birth to death and decomposition, microbial communities act as a dynamic component of the body. Investigating the natural and induced changes in our microbiota has the potential to revolutionize our understanding of human biology.

Microbial succession is defined as a change in the presence, relative abundance or absolute abundance of one or more organisms within a microbial community. Microbial succession processes can be deterministic or stochastic. Factors that drive deterministic succession fall into three categories: abiotic factors (for example, pH or redox potential)⁶, environmental factors (for example,

cross-feeding⁷, diet⁸ or travel⁹) and biological factors (for example, innate and adaptive immunity)¹⁰. Stochastic succession is defined as microbial community changes that are not the consequence of environmentally determined fitness (also called 'ecological drift')^{11,12}. Whether microbial succession is more deterministic or stochastic is driven by several factors in the formation of the community, including birth mode, travel, diet (for example, human breast milk) and antibiotics^{13–17}. There are three main stages of microbial succession that naturally occur across human life during normal or healthy ageing.

The first stage, primary succession, begins at birth when pioneer species first establish the community, and this stage is followed by rapid changes in the microbial community. The rate of change decreases from birth until childhood, and many intermediate species exist between birth and late childhood^{13–15} (FIG. 1, columns 2–4). Primary succession ends at the formation of a climax community, thought to be achieved by adolescence and largely sustained through adulthood; this community is characterized by its relative stability^{18,19} (FIG. 1, column 4). Although the microbiota is stabler in adulthood than in childhood, there is still variability, fuelling the debate over the existence of a climax community in the human microbiota²⁰. Natural variation in the adult microbiota exists on the timescale of hours (circadian rhythms)²¹ to years (ageing), but microbiotas are relatively stable except in the presence of a disturbance, such as a change in diet or medications. The next stage, secondary succession, occurs when part of nearly all of a pre-existing

✉e-mail: robknight@ucsd.edu
<https://doi.org/10.1038/s41579-022-00768-z>

Keystone community members

Microbial species that have an exceedingly large impact on the stability, or recovery after perturbation, of the whole ecosystem.

Alpha diversity

A measure of within-sample diversity.

Beta diversity

A measure of similarity between samples.

stable community is altered or removed, followed by regeneration of the community to either the same state or a different state. This can happen either deliberately, through medical treatments such as antibiotics^{22,23}, or spontaneously, through diseases such as infection with *Vibrio cholerae*²⁴. Secondary succession in humans is characterized by at least some period of a **stochastic process dominating**. In induced conditions, such as a single course of antibiotics, the community follows a process similar to primary succession, in which parts of the existing microbial community act as ‘microbial memory’ and help re-establish a community similar to the one that existed before. This process is thought to be driven by **keystone community members**^{25,26} rather than the pioneer microorganisms that drive primary succession (FIG. 1, columns 5–7). Third, final succession is part of the natural host senescence and death. During old age, the microbial community again succeeds at an increased rate of change, producing a community composed of fewer total members, usually with increased relative abundance, and sometimes total dominance, of the phylum Proteobacteria (also known as Pseudomonadota)^{27,28} (FIG. 1, column 8).

Unlike the human genome, which is encoded at birth and cannot be altered during life (at least with current technology), each of these unique microbiota changes can be deliberately modified across time. Within an individual, the specific body site location, the geographical location and the individual’s age have the strongest relationship with the healthy microbiota of any physiological or demographic variable measured to date¹⁸. Age drives both **alpha diversity** and **beta diversity** in human microbiotas (FIG. 2 and Supplementary Fig. 1). Studying each stage of succession enables researchers to address how human-associated microbial communities are formed and maintained. By understanding these processes, we may better understand how to manage microbiotas as we age and in relation to human health. Although the methods to measure and describe microbial communities are an area of active development, standard practices do exist, making it possible to integrate results across cohorts.

Primary succession in early life

The first factors that shape a human microbiota come from the mother during fetal development. The fetus is exposed to metabolites produced by the mother’s

microbial community through the placenta, which imprint its immune system and can affect both the normal microbiota and also various aspects of pathology later in life (immune imprinting described in²⁹)^{30–32}. The composition and transfer of these metabolites to the fetus can be impacted by the mother’s health, diet and use of antibiotics during pregnancy^{33–39}. For example, the mother’s gut microbiota ferments dietary fibre, resulting in short-chain fatty acids such as acetate which have been observed to cross the placenta³³. Acetate in the fetal tissue affects epigenetic imprinting linked to the generation of regulatory T cells in adults, which are associated with protection from the development of asthma later in life³³. Microbial metabolites (including short-chain fatty acids) and ligands regulate the host aryl hydrocarbon receptor (AHR), which helps to shape the neonatal microbial and immune development^{34,40–42}. Maternal antibiotic use and gastrointestinal tract-related diseases such as inflammatory bowel disease (IBD) are also thought to increase the risk of pathology in offspring later in life by imprinting of the fetal immune system^{43–46}. However, these links have been studied only in non-human experiments. In one case, germ-free mice colonized by microbiotas from either pregnant mothers with IBD or their newborn baby went on to develop the aberrant microbiota and immune development indicative of IBD⁴⁵. The mother’s microbiota and immune system are also altered during pregnancy^{47,48}. The mother’s vaginal microbiota becomes more diverse, consisting of many microorganisms conventionally found at other body sites⁴⁹. The maternal immune system during pregnancy forms cooperative interactions with the fetus, including transferring IgG antibodies across the placenta (reviewed in REFS.^{50,51}) (FIG. 3a).

The beginning of the human microbial community and the start of primary succession occur at birth with the seeding of the newborn from the mother’s microbiota. There is some debate about whether the microbiota obtained at birth originates from both vaginal and faecal sources, through mixing, or whether the vaginal microbiota itself is pluripotent at birth and is the main source of microbial pioneers (that is, the first species to colonize, setting the stage for other species later in succession)^{49,52–54}. Regardless of the exact maternal source, this stage is characterized by pioneer bacterial species such as *Lactobacillus*, *Enterobacter*, *Escherichia*, *Bacteroides*, *Parabacteroides* and *Prevotella*, which then colonize their conventional body sites: the gut, mouth and skin^{15,18,55,56}. Many pioneer bacteria are facultative anaerobes, which deplete oxygen and thereby enable obligate anaerobes to colonize each environment later. At first, each body site of a newborn is relatively undifferentiated, but pioneer microorganisms quickly begin initiating a cascade of body site-dependent microbial diversity, and at least the bacteria at each site can be easily distinguished by the fourth to sixth week of life^{1,13} (FIG. 3b).

The development of the bacterial community in the human gut has been well studied (reviewed in REF.⁵⁷). *Bifidobacterium* spp. are dominant until they give way to a combination of *Bifidobacterium*, *Clostridium* and *Bacteroides* spp. by the end of the first year of life. This is followed by a greater increase in the abundance of

Author addresses

¹Department of Paediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA.

²Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA, USA.

³Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA, USA.

⁴Biomedical Sciences Program, University of California, San Diego, La Jolla, CA, USA.

⁵Department of Animal Sciences, Colorado State University, Fort Collins, CO, USA.

⁶Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.

⁷Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.

⁸Sam and Rose Stein Institute for Research on Aging, University of California, San Diego, La Jolla, CA, USA.

⁹Department of Computer Science and Engineering, University of California, San Diego, La Jolla, CA, USA.

¹⁰Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA.

¹¹These authors contributed equally: Cameron Martino, Amanda Hazel Dillmore.

Bacteroides spp., a more diverse set of genera within the phylum Firmicutes (also known as Bacillota; for example, *Clostridia*, *Faecalibacterium*, *Ruminococcus* and *Veillonella*) and a relative decrease in the abundance of species such as those in the genus *Bifidobacterium*^{14,15,52}. *Bifidobacterium* spp. catabolize human milk oligosaccharides (HMOs) from the mother's breast milk, which is believed to begin imprinting the immune systems for life^{58–61}. Most recently, a study found functional links between bacteria such as *Bifidobacterium* spp. containing genes required for catabolism of HMOs and the infant immune development. In particular, faecal waters from infants that received *Bifidobacterium infantis* EVC001 polarized naive T cells differently from faecal waters

from the control group, in a manner associated with decreased intestinal inflammation⁵⁸. However, species in other genera, such as *Bacteroides* and *Akkermansia*, can also degrade HMOs⁶². By the age of 3–6 years, the gut bacterial community converges to the climax community sustained throughout adulthood. This community of microorganisms is one of the densest and most diverse ecologies known^{63,64}. Usually, only two bacterial phyla are dominant in an average healthy person during this time: Firmicutes and Bacteroidetes⁶⁵.

The virome, mycobiome and archaeome are far less explored than the bacteriome during the course of human gut development. Throughout life, the mycobiome accounts for far fewer total numbers than the




Fig. 1 | The succession of the human microbiota from conception to death. The diversity of resident bacteria, fungi and viruses changes across human life stages. The analogue clock represents the relative time of the host age at which each microbial community stage develops. Immune imprinting begins before birth through the mother's microbiota and its metabolites (first column). Initial colonization of pioneer species begins at birth, and body site-specific microbial communities emerge (second column). These communities continue to increase in complexity until they reach a relatively stable community structure (third and fourth columns). Secondary successions of these microbial communities can occur from

internal and external perturbations (fifth column). Intermediate species of microorganisms re-establish the initial community and reach a steady state again (sixth and seventh columns). At late age, the community goes through a final succession and changes as the host nears natural death (eighth column). The last stage of microbial succession occurs at putrefaction and decomposition. During this stage, diversity further declines and, during the first 24–48 h, many of the human microbiota structures are conserved, but then quickly begin to erode (ninth column). The relative strength of adaptive immunity (green line) and innate immunity (blue line) across different stages of life and microbial succession (bottom) is shown.




Fig. 2 | Measurements of bacterial diversity across age. The bacterial diversity and phylogenetic history of the human faecal (part **a**), oral (part **b**) and skin (part **c**) microbiotas from childhood to old age measured in the data set of the American Gut Project, a citizen science project containing 21,919 faecal, 1,920 oral and 998 skin microbiota samples with 16S ribosomal RNA gene amplicon sequencing⁵⁶. Alpha diversity, a quantitative measure of the number of different types of microorganisms in a sample, measured through Faith's phylogenetic diversity (PD) alpha diversity metric across age (left column). The UniFrac beta diversity principal coordinate analysis, a method for comparing the similarity of microbial communities where spatially close dots represent similar samples and spatially distant dots represent dissimilar samples, coloured by age (right column).

Podoviridae and *Myoviridae* are prevalent immediately after birth, primarily in lysogenic form (integrated into the bacterial genome)^{72,73}. By the fourth month of life, the phage order *Caudovirales* grows in abundance and members are more often lytic (infectious phage particles or actively replicating phages)^{74–76}. In adults, *Caudovirales* and *Microviridae* dominate the gut phage community, but the phage gut virome is highly specific to the individual, and much is still unknown about its succession (reviewed in REF.⁷⁷). Unlike phages, the gut virome of eukaryote-infecting viruses is mostly associated with pathology both in children (for example, gastroenteritis)⁷⁸ and in adults⁷⁹. Recently, some eukaryote-infecting viruses have also been observed in low abundance both in healthy children and in healthy adults but their timing and prevalence are unknown^{72,73,80} (FIG. 3b–d, gut columns).

The oral bacteriome has a high prevalence of members of the genera *Streptococcus*, *Gemella*, *Granulicatella* and *Veillonella* at birth⁸¹. In the following months, the genera *Lactobacillus* and *Fusobacterium* also become prevalent. The abundance of *Staphylococcus* peaks at around 3 months of life and then steadily decreases, giving way to a higher abundance of *Gemella*, *Granulicatella*, *Haemophilus* and *Rothia* spp.⁸². After the formation of teeth, the oral microbiota shifts again, to have a higher abundance of the phyla *Fusobacteriota*, *Synergistetes*, *Tenericutes*, *Saccharibacteria* (TM7) and *SR1* into adulthood^{83–86}. The oral mycobiome is believed to harbour less fungal diversity than the skin and gut⁸⁷. *Candida* spp. are the first fungal colonizers of the oral cavity, on the first day of life^{87,88}. Very little is known of the intermediate oral fungal community, but by adulthood *Candida*, *Cladosporium*, *Aureobasidium*, *Aspergillus*, *Fusarium* and *Cryptococcus* spp. have high prevalence⁸⁹. The oral archaeaome during development is not well understood, but the adult oral cavity harbours many archaeal methanogens, including of the genus *Methanobrevibacter*^{90–92}. To our knowledge, not much is currently known about the colonization of the oral cavity by viruses in human infants. In adults, similarly to the gut, the most common phage group is *Caudovirales*^{4,93,94}. The eukaryotic oral viral community is generally viewed as pathological in nature (for example, Coxsackie A virus, Morbillivirus, Rubulavirus and human papillomavirus), and there are no longitudinal studies of viral

bacteriome or virome. The fungal community in the first few days of life contains a high abundance of *Rhodotorula* and *Debaryomyces* spp., followed in the next month by *Candida*, *Cryptococcus* and *Saccharomyces* spp.^{2,66}. By adulthood, the dominant fungal genera are *Aspergillus*, *Candida* and *Saccharomyces*^{67–69}. The archaeal gut community during development is not well understood, but archaea are some of the earliest colonizers but in low abundance⁷⁰. Early-colonizing archaea include the genera *Methanospaera* and *Methanobrevibacter*⁷⁰. The viral community, consisting mainly of phages, is numerous in the first week of life⁷¹. The phage families *Siphoviridae*,

community composition⁹⁵. However, many eukaryotic viral taxa have also been observed in asymptomatic and otherwise healthy adults⁹⁶ (FIG. 3b–d, oral columns).

The skin bacterial community contains a high abundance of the mother's vaginal *Lactobacillus* spp. at birth^{13,49}. By week 4–5 the infant skin microbiota resembles the adult skin microbiota, but continues to become more site specific into adolescence, with dominant genera such as *Staphylococcus* and *Corynebacterium* across sites and *Pseudomonas*, *Enterobacter*, *Enterococcus*, *Proteus* and *Klebsiella* at specific sites (for example, armpit

versus forearm)^{1,97}. In the skin mycobiome, species of the genera *Malassezia*, *Candida*, and *Saccharomyces* are most prevalent in the first 30 days of life^{2,98,99}. Little is known about the exact compositions of the intermediate community, but the adult mycobiome often has a high abundance of *Malassezia* species, with estimates ranging from 75% to 90% of the total fungal community composition^{2,100}. Little is known of the development of the archaeal community of the skin, but archaea constitute around 4% of the adult community¹⁰¹. Broadly, the adult archaeal skin community is represented by the




Fig. 3 | Primary succession in utero and during early life. The future of the yet-to-be-colonized fetus is set on an initial community assembly trajectory through the priming of each body site by the mother's imprinting on the fetal immune system. Metabolites such as short-chain fatty acids (for example, acetate) and other microbial compounds can be transferred to the fetus through the placenta and influence immune development. The mother's diet and health also influence these metabolites (panel a). Upon birth, the microbial community quickly differentiates by body site (panel b). During this initial

colonization, the pioneer species and the community development of the next 4 years can be impacted by birth mode and gestation time. The following intermediate community is shaped by the diet, such as the consumption of breast milk or formula, and the environment (panel c). Finally, the stable climax community is again shaped by the diet and the environment (panel d). The key (bottom) is composed of fungal, bacterial and viral clades shown in differing colours and distinct representative morphologies. The presence or absence of different clades represents the description in the main text.

Secondary bile acids
Bile acids that have been
altered by the microbiota.

phyla Thaumarchaeota and Euryarchaeota. The archaeal family Halobacteriaceae and genus *Methanobrevibacter* are also found on adult human skin^{102,103}. Unlike the gut and oral cavity, the healthy skin microbiota harbours relatively little known viral diversity, and few studies have been devoted to it, likely due to the technical limitations associated with low-biomass samples¹⁰⁴. However, there are some naturally residing viral populations on the skin¹⁰⁵ (FIG. 3b–d, skin columns).

Several factors shape and differentiate microbial community development in the first few years of life. Birth mode and maternal antibiotic use are among the best-studied and clearest factors that influence the human microbial community. However, microbial development can lead to unique outcomes, even in cohabitating identical twins, likely due to many unknown or stochastic processes¹⁰⁶. The process of natural microbial community establishment can be disrupted, in all body sites, through caesarean delivery and perinatal and neonatal antibiotic exposure^{13–15,107–109}. This finding highlights the importance of the vaginal microbial community, which naturally contains a high abundance of *Lactobacillus* spp. but is altered during puberty, menopause and pregnancy, and is central to female health (reviewed in REFS.^{110,111}). Several of the best-sampled infant development studies, commonly abbreviated as DIABIMMUNE¹⁴ ECAM¹⁵ and TEDDY¹⁰⁸, followed up infants for the first 2 and 3 years of life, and focused on the impacts of antibiotic use or birth mode. In all aforementioned studies, infants born vaginally had higher relative abundance of *Bacteroides* spp. than those born by caesarean delivery. The lack of a natural pioneer microbiota to establish the microbial community results in a more variable community composition thought to be driven more by a stochastic process than a deterministic process, with the effects of birth mode on microbial community composition still observable until the fourth year of life^{112,113}. An exception to the impact of birth mode is preterm birth, likely due to the high use of antibiotics in the first few days of life, which is characterized by an unstable microbial development regardless of the birth mode (reviewed in REF.¹¹⁴). This alteration in the natural development of the infant microbiota is associated with increased risks of infections, immune diseases, obesity and neuroendocrine abnormalities^{107,115–125}. Second, breastfeeding has a large effect on microbiota development compared with other factors¹⁰⁸. The use of formula compared with breastfeeding leads to a higher-diversity and less deterministic microbial community¹²⁶. For example, given the natural dominance of Bifidobacteriaceae in the gut at birth, the lack of certain HMOs as a primary nutrient source can lead to instability in the initial colonization⁵⁸. However, much of the multi-omics integration of the microbiota, milk metabolome and immune system development is an area of active and rapidly advancing research¹²⁷. In addition to HMOs, breast milk also contains other immunomodulatory compounds, such as lipopolysaccharide from Gram-negative bacteria, secretory IgA, innate immune factors, antimicrobial peptides and prebiotic factors^{34,128–131}. Finally, all of these factors impact human immune development. Microorganism-associated

molecular pattern recognition receptors (for example, Toll-like receptors¹³² and NOD-like receptors¹³³) interact with microbiota-derived molecules (for example, lipopolysaccharide), metabolites such as short-chain fatty acids (which interact with GPR43, GPR41 and GPR109)³³ and secondary bile acids (which interact with FXR)¹³⁴ to directly impact immune development^{135,136}. Together, many of these factors contribute to the development of a unique, relatively stable microbial community of bacteria, fungi and viruses, which persists for a large part of the human lifespan.

Secondary succession in adult life

Although the adult microbial community is largely stable compared with the big changes that occur during primary succession in infancy, the community can be perturbed and pushed away from the climax community state. The understanding of the microbiota during health and disease is a deepening and disease-specific research field^{199,137,138}. The genomes of certain bacteria evolve across time in healthy adults, demonstrating that functional and compositional evolution occur in a steady state during secondary succession¹³⁹ (FIG. 4a). There are also natural short-term changes that occur in the adult microbiota on timescales of a day to months or years (FIG. 4a). One well-characterized example of short-term changes is the circadian rhythm in microbial community composition. Human gene expression and immune activation linked to the circadian rhythm¹⁴⁰, and the abundance and composition of bacteria within the gut microbiota also follow this pattern²¹. Bacterial families showing a diurnal cycle in mice include Ruminococcaceae, Lachnospiraceae, Muribaculaceae (S24-7), and Verrucomicrobiaceae, but little is known about equivalent cycles in humans because they produce faeces less frequently than do mice¹⁴¹. In the mouth, daily oscillations in whole groups of fungi and bacteria coincide with brushing¹⁴². On the skin, daily fungal and bacterial alterations coincide with washing and depend on personal care products^{143,144}. A well-studied example of changes that occur on the scale of weeks to years is diet-driven alteration of the gut microbiota. Diet has a large effect on microbial communities, and can include natural and reversible changes in the community (reviewed in REF.¹⁴⁵). For example, the Hadza tribe of Tanzania, who eat a diet rich in meat and tubers in the dry season but a diet rich in honey and berries during the wet season, exhibit large seasonal fluctuations in genera such as *Bacteroides*^{8,145,146}. The large influence of diet in shaping the microbiota may also play a role in human health (reviewed in REF.¹⁴⁷), and much work is being dedicated to understanding how specific dietary components, and dietary patterns overall, influence the microbiota and its impact on health. For example, Western diets, with high levels of red meat, have been linked to all-cause mortality¹⁴⁸. The gut microbiota can act in a deleterious manner to convert L-carnitine, which red meat is rich in, to trimethylamine, and the liver converts trimethylamine into trimethylamine N-oxide, which is hypothesized to promote atherosclerosis¹⁴⁹. The gut microbiota can also act in a protective manner, for example, by cleaving carcinogenic molecules from

red meat before they are absorbed in the gut, protecting from inflammation¹⁴⁶. Besides diet, many other factors help to shape the adult microbiota, including genetics, geography, host factors such as metabolic disease and medicines (reviewed in REF.¹⁵⁰).

Secondary successions that occur due to a disruption in the microbial community have been studied and reviewed extensively. Of the many factors that disrupt the microbiota, antibiotics are among the strongest, often with individually variable recovery after treatment^{22,23}.

The ability of the gut microbial community to rebound after antibiotic treatment is thought to depend on specific community members, such as *Bacteroides thetaio-*
taomicron and *Bifidobacterium adolescentis*^{25,26}. Disease itself can also disrupt the microbiota, whether the change is initiated within the microbial community (overgrowth of a pathogen), from the host or from a combination of factors (reviewed in REF.¹⁰) (FIG. 4b). Many other diseases in the gut, such as IBD, disrupt the microbial community but do not reach a new stable community composition,




Fig. 4 | Secondary succession in adolescence and adult life. Compared with microbial community assembly in primary succession and human development, the microbial community in adulthood is relatively stable. There are natural dynamics and changes to this community, such as microbial oscillations that correlate with host circadian rhythms by day and night or changes in the diet or season (panel a). Secondary succession occurs when there is a disturbance, which can have many causes, with antibiotics being one of the clearest examples. This disruption can cause microbial community members to be lost or fall below the level of detection and large

changes in microbial dynamics, such as the amplitude or periodicity. During this stage, keystone species, similarly to pioneer species, play a key role in preventing the overgrowth of opportunistic pathogens. Soon after, the intermediate community forms with the return of aerotolerant taxa and facultative anaerobes. Finally, the community resembles the initial community with the return of obligate anaerobes (panel b). The key (bottom) is composed of fungal, bacterial and viral clades shown with differing colours and distinct representative morphologies. The presence or absence of different clades represents the description in the main text. *E. coli*, *Escherichia coli*.

but rather continue to be chronically unstable in the absence of intervention (reviewed in REF.¹⁵¹). On the skin, atopic dermatitis is characterized by a bloom in *Staphylococcus aureus* and a decrease in bacterial diversity, induced by immune-mediated inflammation¹⁵². A decrease of abundance of the fungal genus *Malassezia* is observed during such *S. aureus* blooms¹⁵³, and vice versa, a fungal abundance increase leads to a decrease of abundance of *S. aureus*, which may be in part due to the ability of the fungi to produce proteases that digest *S. aureus* biofilms and reduce the bacterium's ability to evade the immune system¹⁵⁴. Similar cross-kingdom interactions also exist in the mouth; for example, colonization of the fungus *Candida albicans* is dependent on bacterial biofilms, but at the same times bacterial genera such as *Pseudomonas* and *Staphylococcus* form competitive and synergistic relationships, respectively (reviewed in REF.¹⁵⁵). These examples highlight how microbial community interactions and successions cross domains and also interact with the host but are still not fully understood due to their complicated nature of higher-order interactions (reviewed in REF.¹⁵⁶).

Obstacles to microbial community recovery after a disturbance have led many researchers to explore the possibility of interventions for targeted restoration of the microbiota. Microbial community restoration involves directed reseeded or enrichment or depletion of certain species, with the intent to induce recovery of a microbial community close to that from before the disturbance. This can be attempted through probiotics, prebiotics, antibiotics or other drugs, transplantation of the complete microbial consortia from a healthy individual¹⁵⁷ or a combination of these. Although these therapies can be highly effective for restoring a healthy microbial community in certain well-characterized contexts^{158,159}, they are often limited by a lack of mechanistic knowledge of their interaction with the existing community¹⁶⁰, or by their ability to engraft only transiently¹⁶¹. To address the mechanisms, researchers have focused on two areas. The first area involves gaining a better understanding of how communities are assembled. For example, the study of human development helps identify how microbial communities assemble during development and the impact of that assembly later in life^{13,49,52,162}. Second, new methods are being developed for determining mechanisms by exploring microbial community interactions both computationally¹⁶³ and experimentally, including high-throughput co-culturing^{164,165} and genome editing of microbial communities¹⁶⁶. To address transience, two main approaches have been applied. First, the transient and individualized impact of microbial community therapeutics is driven by the individual nature of each person's microbiota¹⁶⁷. Therefore, precision medicine, where community alteration is targeted to each person's unique microbiota, holds great promise. For example, personalized nutrition based on microbial community compositions effectively modified postprandial blood glucose in a blinded randomized controlled intervention¹⁶⁸. Second, going beyond the bacteriome to explore the virome and mycobiome, and their interkingdom interactions, holds great promise. For example, phage therapy has already been used in severe cases of drug-resistant

bacterial infections¹⁶⁹, and is highly specific to the target bacterial strains¹⁷⁰. While exciting, most such interventions are still in their preliminary phases of research and are cost-prohibitive at scale.

Late succession in late life

Ageing due to both biological programming and accumulation of damage throughout life impacts every aspect of cellular function, and the microbiota is no exception¹⁷¹. With advanced age, the gut microbiota alpha diversity decreases and the beta diversity (variation between individuals) increases^{19,28,69,172,173}. Much is still unknown about the microbiota in old age, and the literature has been somewhat contradictory (for example, Claesson et al.¹⁷⁴ reported increased abundance of *Bacteroides* spp. in adults aged 65 years and older, contradicting other studies), and most research has focused on gut bacteria. Generally, the community succession observed in the gut is a decrease in the abundance of bacterial genera dominant and prevalent in younger adults (aged 25–45 years), such as *Bifidobacteria*, *Bacteroides* and *Lactobacillus*, often with a decrease in the ability to fend off blooms of opportunistic bacteria such as Enterobacteriaceae and *Clostridium* spp.^{65,174,175}. Skin bacteria of the genera *Cutibacterium* (formerly *Propionibacterium*) and *Staphylococcus* decrease in abundance in those aged 65 years and older, with a greater abundance of *Corynebacterium* being observed¹⁷⁶. In the oral body site, *Rothia* and *Streptococcus* spp. dominate the core oral bacterial community, with consistent decreases in the abundance of *Porphyromonas*, *Treponema* and *Faecalibacterium* spp.^{177,178}. The gut mycobiome in old age is characterized by an increased dominance of *Penicillium*, *Candida*, *Aspergillus* and *Saccharomyces* spp.^{67,69,179}. In the skin and oral body sites, very few studies exist, but old age is characterized by a decreased abundance of *Malassezia* spp. in the skin and *Candida* spp. in the oral cavity¹⁸⁰. In gut phages, dominance of *Siphoviridae* in adulthood gives way to dominance of *Microviridae*, *Podoviridae* and crAssphages in old age¹⁹. In contrast to gut bacterial, fungal and phage populations, eukaryotic viral diversity stays constant after childhood throughout the rest of life¹⁹ (FIG. 5a).

Due to the high variability between individuals, the focus of research into microbial succession in old age has primarily been in the comparison of healthy and unhealthy ageing. It remains unclear whether the microbiota has a mechanistic role in healthy ageing or is just a strong indicator of other variables, such as diet, exercise and medications (reviewed in¹⁸¹). However, in those who live longer and healthily, commonalities can be observed in sustained retention of those taxa highly prevalent in healthy adults such as *Bacteroides* spp.¹⁸². However, centenarians exhibit a more unique microbiota with increased alpha diversity and greater inter-individual differences in community composition, complicating the comparison between 'healthy' and 'unhealthy' ageing^{28,172,173} (FIG. 5b). Secondary bile acids are enriched in centenarians and may also have a role in healthy ageing¹⁸³. Although promising, this area of research is still underpowered and emerging.




Fig. 5 | Late succession approaching the end of life. The adult stable microbial community transitions to a final community in old age (panel **a**). The exact timescale of ‘old age’ depends on several other host-related factors, such as disease, but most literature to date defines ‘older adults’ as those aged 65 years and older. Healthy ageing is generally associated with a delayed transition to the final community (panel **b**, top). The final community characteristics are lower alpha diversity and increased uniqueness compared across different people of the same age (panel **b**, bottom). The key (bottom) is composed of fungal, bacterial and viral clades shown with differing colours and distinct representative morphologies. The presence or absence of different clades represents the description in the main text.


The microbiota after death

Microbial succession does not end with the death of an individual, and host death can be viewed primarily as an ecological disturbance of the microbiota. Immediately following cessation of the heart, tissues begin to break down due to the lack of oxygen^{184,185}. Cellular functions continue until all the remaining oxygen is depleted and carbon dioxide is no longer able to be transported from the tissue^{184,185}. The intracellular build-up of carbon dioxide creates a hypoxic, acidic environment, leading to cell rupture^{185,186}. Cellular components, such as enzymes (for example, lipases), leak into the surroundings, where they further facilitate tissue breakdown in a process called ‘autolysis’¹⁸⁶. Autolysis triggers a cascade of microbial processes responsible for tissue breakdown (that is, putrefaction) by eliminating the immune system, loosening cellular junctions and providing nutrients to the microbiota^{185–187}. During the first few days

to weeks of decomposition, putrefaction is performed mostly by bacteria, but fungi have an increased role as decomposition progresses^{188–191} (FIG. 6a). However, little is known about the virome succession and functional role during this process.

The human microbiota is relatively stable during the first 24–48 h after death, with distinct body site microbial ecologies¹⁹¹, alpha diversity patterns by age¹⁹¹ and identifiable personalized skin microbiota signatures¹⁹². Afterwards, the cascade of environmental changes facilitates a microbial succession that alters the human body and microbiota in a way that no longer resembles a living individual (unless the body is cooled or frozen). The dearth of environmental constraints previously encountered in host life enables rapid changes in the relative abundance of microorganisms^{189,191,193} as well as movement across body sites^{187,194,195}. Migrating bacterial groups become pioneer species that translocate from

a Post-mortem timeline



b Post-mortem microbiota fingerprint




Fig. 6 | The microbiota after death. After death the microbiota is relatively stable in the first 24–48 h. The tissue then begins to break down during autolysis, leading to bloom in the gastrointestinal microbiota and a decrease in alpha diversity and a decrease in beta diversity between body sites. During putrefaction, the role of fungi increases, and the microbiota of the body becomes more similar to the microbiota of the surrounding environment (part a). The post-mortem microbiota is unique to each body and is distinct between bodies on the basis of the time since death, cause of death, environment, location and age at death, and, at the beginning, between body sites (part b).

the intestinal tract to extraintestinal sites, participating in either primary succession or secondary succession depending on the body site^{195,196}. As the time after death increases, alpha diversity of communities generally decreases (as is expected with nutrient pulses) and community composition (that is, beta diversity) becomes more similar across body sites^{189,197,198}. The gut and the skin are the two best-studied human post-mortem microbial ecologies. Interestingly, the post-mortem community succession in the gut follows trends also detected in old age, with decreases in the relative abundance of *Bacteroides* and *Lactobacillus* spp. and an increase in the relative abundance of *Clostridium* spp. and taxa in the family Enterococcaceae^{190,193,197,199}. The post-mortem composition and succession of skin microbial communities depends on the external environment. For example, if exposed to soil, most post-mortem microorganisms, as well as nematodes, assemble from soil communities¹⁸⁹.

The microbiota of death has attracted increased attention due to its implications for forensic investigations. The consistent temporal patterns of succession associated with multiple individuals and body sites are evidence that the post-mortem microbiota may serve as a bioindicator of the post-mortem interval^{189,193,197,198,200}. Post-mortem interval estimations are more accurate during the earlier stages of decomposition (that is, the first 2–3 weeks after death), when microbial succession includes rapid turnover of community members^{197,201}, but are still useful in later stages of decomposition (for example, in bone), when few lines of evidence exist for estimating the post-mortem interval^{202,203}. Connections with the cause of death and microbial presence have also been demonstrated¹⁹¹. For example, increased detection of *Rothia* spp. was found in the oral microbiota of individuals who died of heart disease¹⁹¹. Moreover, skin microbiota shedding may contribute to trace evidence by connecting individuals with items they have

interacted with such as mobile phones^{192,204}; however, the time this unique signature can be accurately matched to an individual depends on the object's material and use¹⁹² (FIG. 6b).

Conclusions and outlook

In this Review, we have described the current understanding of human resident microbial community composition across ages and different body sites. The many connections between human health and our microbial community composition are bringing an increasing interest in interventions. Interventions that focus on the whole microbial community, rather than the enrichment or elimination of a single species, require an understanding of how these communities are formed and maintained. Through studying microbial communities across the human lifespan, we may better understand these complex interactions and how to effectively push the community to a desired composition for the host. Moreover, as discussed here, these insights are being applied in several other areas, such as in forensics.

Although this Review has focused on the microbiota and its associations with healthy ageing, many conditions have been associated with accelerated ageing, and are just beginning to be studied in a microbiota context, a key example being schizophrenia²⁰⁵. Social determinants of health have a major impact on health, ageing and longevity, in the context of both healthy ageing and pathological ageing. These factors include education, poverty, occupation, discrimination and social connections²⁰⁶. Since many of these factors have also been linked to the microbiota, understanding the role of these social determinants and how to modify their effects to promote healthy ageing will be an important topic for future research linking the microbiota and ageing.

Despite the enormous effort and resources being put into characterizing the microbiota, we have just

Box 1 | Sampling and quantifying microbial communities**Study design and sample collection**

The human microbiota is dynamic²⁰⁹. With this in mind, it is important to design a sampling strategy that can capture the temporal and spatial variability of the microbiota, particularly when these fluctuations are relevant to the scientific questions asked. Cross-sectional studies collect a single sample from each individual, while repeated-measures studies collect samples at multiple time points or body sites. With time, the frequency of sampling should be tuned to the phenomenon researchers are attempting to observe. For example, murine circadian rhythm studies typically collect faecal samples every 2–4 h (REF²¹⁰), while in inflammatory bowel disease, sampling patients between three times and five times over a period of weeks can improve disease classification²¹¹. In other applications, such as studying the effect of particular treatments on an individual's microbiota, it may be relevant to perform an 'n-of-one' study, in which the same participant is repeatedly probed for resultant changes in his or her microbiota; samples collected before treatment are regarded as individual-level controls²¹².

It is also important to consider that the microbiota of a population is highly dependent on geography and ethnicity. For example, one of the microorganisms most highly associated with age in a large Chinese cohort was not detected at all in a large American cohort¹⁵³. Another specific example pertains to the 'built environment' of urbanized societies; urbanized populations generally have less exposure to environmental microorganisms and higher use of household antimicrobials, resulting in significant shifts compared with the human microbiota from rural societies²¹³. These considerations are particularly relevant for the microbiota field, as most public microbiota data come from urbanized North American and European populations¹⁸³. Therefore, conclusions from existing data sets may not generalize well to the global population.

Data generation

The main categories of sequencing data that are generated from human microbiota and microbiome studies are amplicon sequencing data and shotgun sequencing data. In amplicon sequencing, the PCR products (amplicons) of established hypervariable regions are deeply sequenced, enabling identification and measurement of community members by matching to their individual 'barcodes'. There are two choices to be made here: the gene to amplify and which portion of that gene to amplify. Commonly amplified regions of microbial genomes include the 16S ribosomal RNA gene for bacteria, the 18S ribosomal RNA gene for eukaryotic microorganisms and internal transcribed spacer for fungi. The choice of the hypervariable region within each specific gene to amplify depends on the particular microorganism to be captured, but broadly, commonly used ones include the V4 region from the Earth Microbiome Project²¹⁴. In shotgun sequencing, all microbial DNA is sequenced instead of only PCR products, enabling a more specific taxonomic classification of microorganisms. Because it does not rely on any marker genes, shotgun sequencing is less biased than amplicon sequencing is towards certain sets of microorganisms. However, shotgun sequencing is considerably more expensive and requires substantially more computational power, making amplicon sequencing attractive in cases in which the increased resolution of shotgun sequencing is not required. An additional concern and outstanding problem in the field is privacy and ensuring that public metagenomic data cannot be used to identify study participants²¹⁵.

Pairing sequencing data with other analyses

Performing amplicon or metagenomic sequencing in conjunction with other techniques, including other omics techniques, can enrich one's understanding of both microbiota and host. Techniques such as quantitative PCR and fluorescence-activated cell sorting provide more context for relative abundances by anchoring them to a reliable absolute abundance measure^{185,186}. Enzyme-linked immunosorbent assay (ELISA) and single-cell sequencing can pair well with metagenomic sequencing by providing host cell type or host immune information¹⁸⁷. Culturomics enables the researcher to experimentally verify genomic predictions of function or activity, as well as to turn the microorganisms into probiotics¹⁸⁸. Microbially produced metabolites or proteins, the downstream effectors of the microbiota, can be probed through metabolomics and proteomics, respectively¹⁸⁹. Finally, host genomics and transcriptomics are increasingly paired with amplicon and/or metagenomic data to provide insight into connections between host gene expression and the microbiota.

Metadata

Finally, it is paramount to collect data from the participants surveyed. Some important categories of metadata for general microbiota studies include demographics, clinical information (that is, other conditions and antibiotic use) and dietary information; however, the exact metadata used will differ by study. Practices for producing standardized metadata should be adopted so that results are reusable and reproducible²¹⁶.

scratched the surface. Moreover, many current challenges and limitations exist, such as skewed geographical sampling, privacy concerns and outstanding issues with data standardization (BOX 1). There are also large disparities in our understanding of microbial kingdoms, mainly due to technical difficulties in characterizing taxa other than bacteria²⁰⁷. The gaps in understanding virome and mycobiome community structure and cross-kingdom interactions are an area of exciting research driven by technical advances that increase the accuracy and decrease the cost of DNA sequencing.

However, contradictions in the field are abundant, especially in those observations driven purely by sequencing data, and more robust analyses are key to consolidating knowledge in the field (for example, log ratios)²⁰⁸ (BOX 1). Studying species beyond relative taxonomic compositions through high-throughput cultivation, metagenomics, transcriptomics and metabolomics is a rapidly expanding area of research that is key to filling in gaps in our understanding¹⁶³.

Published online 29 July 2022

1. Chu, D. M. et al. Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery. *Nat. Med.* **23**, 314–326 (2017).
2. Ward, T. L. et al. Development of the human mycobiome over the first month of life and across body sites. *mSystems* **5**, e00140–17 (2018).
3. Oh, J. et al. Biogeography and individuality shape function in the human skin metagenome. *Nature* **514**, 59–64 (2014).
4. Abeles, S. R. et al. Human oral viruses are personal, persistent and gender-consistent. *ISME J.* **8**, 1753–1767 (2014).
5. Grice, E. A. & Segre, J. A. The human microbiome: our second genome. *Annu. Rev. Genomics Hum. Genet.* **13**, 151–170 (2012).
6. Lauber, C. L., Hamady, M., Knight, R. & Fierer, N. Pyrosequencing-based assessment of soil pH as a predictor of soil bacterial community structure at the continental scale. *Appl. Environ. Microbiol.* **75**, 5111–5120 (2009).
7. Zengler, K. & Zaramela, L. S. The social network of microorganisms - how auxotrophies shape complex communities. *Nat. Rev. Microbiol.* **16**, 383–390 (2018).
8. Smits, S. A. et al. Seasonal cycling in the gut microbiome of the Hadza hunter-gatherers of Tanzania. *Science* **357**, 802–806 (2017).
9. Rasko, D. A. Changes in microbiome during and after travellers' diarrhea: what we know and what we do not. *J. Travel. Med.* **24**, S52–S56 (2017).
10. Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. *Cell Res.* **30**, 492–506 (2020).
11. Zaneveld, J. R., McMinds, R. & Vega Thurber, R. Stress and stability: applying the Anna Karenina principle to animal microbiomes. *Nat. Microbiol.* **2**, 17121 (2017).
12. Dini-Andreote, F., Stegen, J. C., van Elsland, J. D. & Salles, J. F. Disentangling mechanisms that mediate the balance between stochastic and deterministic processes in microbial succession. *Proc. Natl Acad. Sci. USA* **112**, E1326–E1332 (2015).
13. Dominguez-Bello, M. G. et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc. Natl Acad. Sci. USA* **107**, 11971–11975 (2010).
14. Yassour, M. et al. Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. *Sci. Transl. Med.* **8**, 343ra81 (2016).
15. Bokulich, N. A. et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. *Sci. Transl. Med.* **8**, 343ra82 (2016).
16. David, L. A. et al. Host lifestyle affects human microbiota on daily timescales. *Genome Biol.* **15**, R89 (2014).
17. Vangay, P. et al. US immigration westernizes the human gut microbiome. *Cell* **175**, 962–972.e10 (2018).
18. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. *Nature* **486**, 222–227 (2012).
19. Gregory, A. C. et al. The gut virome database reveals age-dependent patterns of virome diversity in the human gut. *Cell Host Microbe* **28**, 724–740.e8 (2020).
20. Faith, J. J. et al. The long-term stability of the human gut microbiota. *Science* **341**, 1237439 (2013).
21. Thaiss, C. A. et al. Microbiota diurnal rhythmicity programs host transcriptome oscillations. *Cell* **167**, 1495–1510.e12 (2016).
22. Zaura, E. et al. Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces. *mBio* **6**, e01693–15 (2015).
23. Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc. Natl Acad. Sci. USA* **108** (Suppl. 1), 4554–4561 (2011).
24. Hsiao, A. et al. Members of the human gut microbiota involved in recovery from *Vibrio cholerae* infection. *Nature* **515**, 423–426 (2014).
25. Chng, K. R. et al. Metagenome-wide association analysis identifies microbial determinants of post-antibiotic ecological recovery in the gut. *Nat. Ecol. Evol.* **4**, 1256–1267 (2020).
26. Gibbons, S. M. Keystone taxa indispensable for microbiome recovery. *Nat. Microbiol.* **5**, 1067–1068 (2020).
27. Rizzatti, G., Lopetuso, L. R., Gibiino, G., Binda, C. & Gasbarrini, A. Proteobacteria: a common factor in human diseases. *Biomed. Res. Int.* **2017**, 9351507 (2017).
28. Biagi, E. et al. Gut microbiota and extreme longevity. *Curr. Biol.* **26**, 1480–1485 (2016).
29. Lim, A. I. et al. Prenatal maternal infection promotes tissue-specific immunity and inflammation in offspring. *Science* **373**, eabf3002 (2021).
30. Al Nabhani, Z. & Eberl, G. Imprinting of the immune system by the microbiota early in life. *Mucosal Immunol.* **13**, 183–189 (2020).
31. Lynn, M. A. et al. Early-life antibiotic-driven dysbiosis leads to dysregulated vaccine immune responses in mice. *Cell Host Microbe* **23**, 653–660.e5 (2018).
32. Blaser, M. J. The theory of disappearing microbiota and the epidemics of chronic diseases. *Nat. Rev. Immunol.* **17**, 461–463 (2017).
33. Thorburn, A. N. et al. Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. *Nat. Commun.* **6**, 7320 (2015).
34. Gomez de Agüero, M. et al. The maternal microbiota drives early postnatal innate immune development. *Science* **351**, 1296–1302 (2016).
35. Macpherson, A. J., de Agüero, M. G. & Ganai-Vonarburg, S. C. How nutrition and the maternal microbiota shape the neonatal immune system. *Nat. Rev. Immunol.* **17**, 508–517 (2017).
36. Nakajima, A. et al. Maternal high fiber diet during pregnancy and lactation influences regulatory T cell differentiation in offspring in mice. *J. Immunol.* **199**, 3516–3524 (2017).
37. Jamalkandi, S. A. et al. Oral and nasal probiotic administration for the prevention and alleviation of allergic diseases, asthma and chronic obstructive pulmonary disease. *Nutr. Res. Rev.* **34**, 1–16 (2021).
38. Örtqvist, A. K., Lundholm, C., Halfvarson, J., Ludvigsson, J. F. & Almqvist, C. Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study. *Gut* **68**, 218–225 (2019).
39. Munyaka, P. M., Eissa, N., Bernstein, C. N., Khafipour, E. & Ghia, J.-E. Antepartum antibiotic treatment increases offspring susceptibility to experimental colitis: a role of the gut microbiota. *PLoS ONE* **10**, e0142536 (2015).
40. Kiss, E. A. et al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. *Science* **334**, 1561–1565 (2011).
41. Lee, J. S. et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. *Nat. Immunol.* **13**, 144–151 (2011).
42. Qiu, J. et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. *Immunity* **36**, 92–104 (2012).
43. Schuler, A. F. et al. Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. *Nat. Microbiol.* **3**, 234–242 (2018).
44. Ma, J. et al. High-fat maternal diet during pregnancy persistently alters the offspring microbiome in a primate model. *Nat. Commun.* **5**, 3889 (2014).
45. Torres, J. et al. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. *Gut* **69**, 42–51 (2020).
46. Milliken, S., Allen, R. M. & Lamont, R. F. The role of antimicrobial treatment during pregnancy on the neonatal gut microbiome and the development of atopy, asthma, allergy and obesity in childhood. *Expert. Opin. Drug. Saf.* **18**, 173–185 (2019).
47. Santacruz, A. et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. *Br. J. Nutr.* **104**, 83–92 (2010).
48. Trevisanuto, D. et al. Fetal placental inflammation is associated with poor neonatal growth of preterm infants: a case-control study. *J. Matern. Fetal Neonatal Med.* **26**, 1484–1490 (2013).
49. Song, S. J. et al. Naturalization of the microbiota developmental trajectory of Cesarean-born neonates after vaginal seeding. *Med* **2**, 951–964.e5 (2021).
50. Abu-Raya, B., Michalski, C., Sadarangani, M. & Lavoie, P. M. Maternal immunological adaptation during normal pregnancy. *Front. Immunol.* **11**, 575197 (2020).
51. Hanson, L. A. et al. The transfer of immunity from mother to child. *Ann. NY Acad. Sci.* **987**, 199–206 (2003).
52. Dominguez-Bello, M. G. et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. *Nat. Med.* **22**, 250–253 (2016).
53. Ferretti, P. et al. Mother-to-infant microbial transmission from different body sites shapes the developing infant gut microbiome. *Cell Host Microbe* **24**, 133–145.e5 (2018).
54. Helve, O. et al. 2843. Maternal fecal transplantation to infants born by cesarean section: safety and feasibility. *Open. Forum Infect. Dis.* **6**, S68 (2019).
55. Subramanian, S. et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. *Nature* **510**, 417–421 (2021).
56. Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A. & Brown, P. O. Development of the human infant intestinal microbiota. *PLoS Biol.* **5**, e177 (2007).
57. Groer, M. W. et al. Development of the preterm infant gut microbiome: a research priority. *Microbiome* **2**, 38 (2014).
58. Henrick, B. M. et al. Bifidobacteria-mediated immune system imprinting early in life. *Cell* **184**, 3884–3898.e11 (2021).
59. Sela, D. A. & Mills, D. A. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. *Trends Microbiol.* **18**, 298–307 (2010).
60. Seppo, A. E. et al. Infant gut microbiome is enriched with *Bifidobacterium longum* ssp. *infantis* in old order mennonites with traditional farming lifestyle. *Allergy* **76**, 3489–3503 (2021).
61. Triantis, V., Bode, L. & van Neerven, R. J. J. Immunological effects of human milk oligosaccharides. *Front. Pediatr.* **6**, 190 (2018).
62. Yu, Z.-T., Chen, C. & Newburg, D. S. Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes. *Glycobiology* **23**, 1281–1292 (2013).
63. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature* **486**, 207–214 (2012).
64. McDonald, D. et al. American gut: an open platform for citizen science microbiome research. *mSystems* **3**, e00031–18 (2018).
65. Odamaki, T. et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. *BMC Microbiol.* **16**, 90 (2016).
66. Schei, K. et al. Early gut mycobiota and mother-offspring transfer. *Microbiome* **5**, 107 (2017).
67. Alonso, R., Pisa, D., Fernández-Fernández, A. M. & Carrasco, L. Infection of fungi and bacteria in brain tissue from elderly persons and patients with Alzheimer's disease. *Front. Aging Neurosci.* **10**, 159 (2018).
68. Nagpal, R. et al. Gut mycobiome and its interaction with diet, gut bacteria and Alzheimer's disease markers in subjects with mild cognitive impairment: a pilot study. *EBioMedicine* **59**, 102950 (2020).
69. Ahmad, H. F. et al. Gut mycobiome dysbiosis is linked to hypertriglyceridemia among home dwelling elderly Danes. Preprint at *bioRxiv* <https://doi.org/10.1101/2020.04.16.044693> (2020).
70. Wampach, L. et al. Colonization and succession within the human gut microbiome by archaea, bacteria, and microeukaryotes during the first year of life. *Front. Microbiol.* **8**, 738 (2017).
71. Breitbart, M. et al. Metagenomic analyses of an uncultured viral community from human feces. *J. Bacteriol.* **185**, 6220–6223 (2003).
72. Liang, G. et al. The stepwise assembly of the neonatal virome is modulated by breastfeeding. *Nature* **581**, 470–474 (2020).
73. Lim, E. S. et al. Early life dynamics of the human gut virome and bacterial microbiome in infants. *Nat. Med.* **21**, 1228–1234 (2015).
74. Liang, G. et al. Dynamics of the stool virome in very early-onset inflammatory bowel disease. *J. Crohns. Colitis* **14**, 1600–1610 (2020).

75. Koren, O. & Rautava, S. *The Human Microbiome in Early Life: Implications to Health and Disease* (Academic, 2020).
76. Reyes, A. et al. Gut DNA viromes of Malawian twins discordant for severe acute malnutrition. *Proc. Natl Acad. Sci. USA* **112**, 11941–11946 (2015).
77. Liang, G. & Bushman, F. D. The human virome: assembly, composition and host interactions. *Nat. Rev. Microbiol.* **19**, 514–527 (2021).
78. Oude Munnink, B. B. & van der Hoek, L. Viruses causing gastroenteritis: the known, the new and those beyond. *Viruses* **8**, 42 (2016).
79. Woolhouse, M., Scott, F., Hudson, Z., Howey, R. & Chase-Topping, M. Human viruses: discovery and emergence. *Phil. Trans. R. Soc. B* **367**, 2864–2871 (2012).
80. Rascovan, N., Duraisamy, R. & Desnues, C. Metagenomics and the human virome in asymptomatic individuals. *Annu. Rev. Microbiol.* **70**, 125–141 (2016).
81. Mason, M. R., Chambers, S., Dabdoub, S. M., Thikkurissy, S. & Kumar, P. S. Characterizing oral microbial communities across dentition states and colonization niches. *Microbiome* **6**, 67 (2018).
82. Dzidic, M. et al. Oral microbiome development during childhood: an ecological succession influenced by postnatal factors and associated with tooth decay. *ISME J.* **12**, 2292–2306 (2018).
83. Merglova, V. & Poleni, P. Early colonization of the oral cavity in 6- and 12-month-old infants by cariogenic and periodontal pathogens: a case-control study. *Folia Microbiol.* **61**, 423–429 (2016).
84. Gomez, A. & Nelson, K. E. The oral microbiome of children: development, disease, and implications beyond oral health. *Microb. Ecol.* **73**, 492–503 (2017).
85. Cephas, K. D. et al. Comparative analysis of salivary bacterial microbiome diversity in edentulous infants and their mothers or primary care givers using pyrosequencing. *PLoS ONE* **6**, e23503 (2011).
86. Crielaard, W. et al. Exploring the oral microbiota of children at various developmental stages of their dentition in the relation to their oral health. *BMC Med. Genomics* **4**, 22 (2011).
87. Darwazeh, A. M. & al-Bashir, A. Oral candidal flora in healthy infants. *J. Oral. Pathol. Med.* **24**, 361–364 (1995).
88. Stecksén-Blicks, C., Granström, E., Silfverdal, S. A. & West, C. E. Prevalence of oral Candida in the first year of life. *Mycoses* **58**, 550–556 (2015).
89. Ghannoum, M. A. et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathog.* **6**, e1000713 (2010).
90. Brusa, T., Conca, R., Ferrara, A., Ferrari, A. & Pecchioni, A. The presence of methanobacteria in human subgingival plaque. *J. Clin. Periodontol.* **14**, 470–471 (1987).
91. Ferrari, A., Brusa, T., Rutili, A., Canzi, E. & Biavati, B. Isolation and characterization of *Methanobrevibacter oralis* sp. nov. *Curr. Microbiol.* **29**, 7–12 (1994).
92. Nguyen-Hieu, T., Khelafia, S., Aboudharam, G. & Drancourt, M. Methanogenic archaea in subgingival sites: a review. *APMIS* **121**, 467–477 (2013).
93. Abeles, S. R., Ly, M., Santiago-Rodriguez, T. M. & Pride, D. T. Effects of long term antibiotic therapy on human oral and fecal viromes. *PLoS ONE* **10**, e0134941 (2015).
94. Pérez-Brocal, V. & Moya, A. The analysis of the oral DNA virome reveals which viruses are widespread and rare among healthy young adults in Valencia (Spain). *PLoS ONE* **13**, e0191867 (2018).
95. Dye, B. A., Li, X. & Thornton-Evans, G. Oral health disparities as determined by selected healthy people 2020 oral health objectives for the United States, 2009–2010. *NCHS Data Brief*. **104**, 1–8 (2012).
96. Baker, J. L., Bor, B., Agnello, M., Shi, W. & He, X. Ecology of the oral microbiome: beyond bacteria. *Trends Microbiol.* **25**, 362–374 (2017).
97. Gaitanis, G. et al. Variation of cultured skin microbiota in mothers and their infants during the first year postpartum. *Pediatr. Dermatol.* **36**, 460–465 (2019).
98. Lee, Y. W., Yim, S. M., Lim, S. H., Choe, Y. B. & Ahn, K. J. Quantitative investigation on the distribution of *Malassezia* species on healthy human skin in Korea. *Mycoses* **49**, 405–410 (2006).
99. Byrd, A. L., Belkaid, Y. & Segre, J. A. The human skin microbiome. *Nat. Rev. Microbiol.* **16**, 143–155 (2018).
100. Sugita, T. et al. Quantitative analysis of the cutaneous *Malassezia* microbiota in 770 healthy Japanese by age and gender using a real-time PCR assay. *Med. Mycol.* **48**, 229–233 (2010).
101. Probst, A. J., Auerbach, A. K. & Moissl-Eichinger, C. Archaea on human skin. *PLoS ONE* **8**, e65388 (2013).
102. Hulcr, J. et al. A jungle in there: bacteria in belly buttons are highly diverse, but predictable. *PLoS ONE* **7**, e47712 (2012).
103. Caporaso, J. G. et al. Moving pictures of the human microbiome. *Genome Biol.* **12**, R50 (2011).
104. Moya, A. & Brocal, V. P. *The Human Virome: Methods and Protocols* (Springer, 2018).
105. Foulongne, V. et al. Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. *PLoS ONE* **7**, e38499 (2012).
106. Turnbaugh, P. J. et al. Organismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins. *Proc. Natl Acad. Sci. USA* **107**, 7503–7508 (2010).
- This study shows that cohabitating identical twins result in different microbial communities, highlighting the many unknown processes that lead to the unique human microbiota.**
107. Shao, Y. et al. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. *Nature* **574**, 117–121 (2019).
108. Stewart, C. J. et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature* **562**, 583–588 (2018).
109. Aïmonen, S. et al. Antibiotics at birth and later antibiotic courses: effects on gut microbiota. *Pediatr. Res.* **91**, 154–162 (2022).
110. Chen, X., Lu, Y., Chen, T. & Li, R. The female vaginal microbiome in health and bacterial vaginosis. *Front. Cell. Infect. Microbiol.* **11**, 631972 (2021).
111. Wells, J. S., Chandler, R., Dunn, A. & Brewster, G. The vaginal microbiome in U.S. black women: a systematic review. *J. Womens Health* **29**, 362–375 (2020).
112. Martino, C. et al. Context-aware dimensionality reduction deconvolutes gut microbial community dynamics. *Nat. Biotechnol.* **39**, 165–168 (2021).
113. Furman, O. et al. Stochasticity constrained by deterministic effects of diet and age drive rumen microbiome assembly dynamics. *Nat. Commun.* **11**, 1904 (2020).
114. Henderickx, J. G. E., Zwiittink, R. D., van Lingen, R. A., Knol, J. & Belzer, C. The preterm gut microbiota: an inconspicuous challenge in nutritional neonatal care. *Front. Cell. Infect. Microbiol.* **9**, 85 (2019).
115. Malamitsi-Puchner, A. et al. The influence of the mode of delivery on circulating cytokine concentrations in the perinatal period. *Early Hum. Dev.* **81**, 387–392 (2005).
116. Stokholm, J. et al. Maturation of the gut microbiome and risk of asthma in childhood. *Nat. Commun.* **9**, 141 (2018).
117. Andersen, V., Möller, S., Jensen, P. B., Möller, F. T. & Green, A. Caesarean delivery and risk of chronic inflammatory diseases (inflammatory bowel disease, rheumatoid arthritis, coeliac disease, and diabetes mellitus): a population based registry study of 2,699,479 births in Denmark during 1973–2016. *Clin. Epidemiol.* **12**, 287–293 (2020).
118. Blustein, J. et al. Association of caesarean delivery with child adiposity from age 6 weeks to 15 years. *Int. J. Obes.* **37**, 900–906 (2013).
119. Ardıc, C., Usta, O., Omar, E., Yildiz, C. & Memis, E. Caesarean delivery increases the risk of overweight or obesity in 2-year-old children. *J. Obstet. Gynaecol.* **41**, 374–379 (2021).
120. Cox, L. M. et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. *Cell* **158**, 705–721 (2014).
121. Martinez, K. A. 2nd et al. Increased weight gain by C-section: functional significance of the primordial microbiome. *Sci. Adv.* **3**, eaao1874 (2017).
122. Olszak, T. et al. Microbial exposure during early life has persistent effects on natural killer T cell function. *Science* **336**, 489–493 (2012).
123. Livanos, A. E. et al. Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. *Nat. Microbiol.* **1**, 16140 (2016).
124. Moya-Pérez, A. et al. Intervention strategies for cesarean section-induced alterations in the microbiota-gut-brain axis. *Nutr. Rev.* **75**, 225–240 (2017).
125. Braniste, V. et al. The gut microbiota influences blood-brain barrier permeability in mice. *Sci. Transl. Med.* **6**, 263ra158 (2014).
126. Forbes, J. D. et al. Association of exposure to formula in the hospital and subsequent infant feeding practices with gut microbiota and risk of overweight in the first year of life. *JAMA Pediatr.* **172**, e181161 (2018).
127. Shenav, L. & Azad, M. B. Using community ecology theory and computational microbiome methods to study human milk as a biological system. *mSystems* **7**, e01132–21 (2022).
128. Kaetzel, C. S. Cooperativity among secretory IgA, the polymeric immunoglobulin receptor, and the gut microbiota promotes host-microbial mutualism. *Immunol. Lett.* **162**, 10–21 (2014).
129. Munblit, D., Verhasselt, V. & Warner, J. O. *Human Milk Composition and Health Outcomes in Children* (Frontiers Media, 2019).
130. Mastromarino, P. et al. Correlation between lactoferrin and beneficial microbiota in breast milk and infant's feces. *Biomaterials* **27**, 1077–1086 (2014).
131. Agus, A., Planchais, J. & Sokol, H. Gut microbiota regulation of tryptophan metabolism in health and disease. *Cell Host Microbe* **23**, 716–724 (2018).
132. Coats, S. R., Pham, T.-T. T., Bainbridge, B. W., Reife, R. A. & Darveau, R. P. MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize *Escherichia coli* lipopolysaccharide at the TLR4 signaling complex. *J. Immunol.* **175**, 4490–4498 (2005).
133. Denou, E. et al. Defective NOD 2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance. *EMBO Mol. Med.* **7**, 259–274 (2015).
134. Quinn, R. A. et al. Global chemical effects of the microbiome include new bile-acid conjugations. *Nature* **579**, 123–129 (2020).
135. Rooks, M. G. & Garrett, W. S. Gut microbiota, metabolites and host immunity. *Nat. Rev. Immunol.* **16**, 341–352 (2016).
136. Vatanen, T. et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. *Cell* **165**, 1551 (2016).
137. Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. *Nat. Rev. Microbiol.* **19**, 55–71 (2021).
138. Xiao, J., Fiscella, K. A. & Gill, S. R. Oral microbiome: possible harbinger for children's health. *Int. J. Oral. Sci.* **12**, 12 (2020).
139. Zhao, S. et al. Adaptive evolution within gut microbiomes of healthy people. *Cell Host Microbe* **25**, 656–667.e8 (2019).
140. Zhang, R., Lahens, N. F., Ballance, H. I., Hughes, M. E. & Hogenesch, J. B. A circadian gene expression atlas in mammals: implications for biology and medicine. *Proc. Natl Acad. Sci. USA* **111**, 16219–16224 (2014).
141. Allaband, C. et al. Intermittent hypoxia and hypercapnia alter diurnal rhythms of luminal gut microbiome and metabolome. *mSystems* **6**, e001116–e00121 (2021).
142. Marotz, C. et al. Quantifying live microbial load in human saliva samples over time reveals stable composition and dynamic load. *mSystems* **6**, e01182–20 (2021).
143. Bouslimani, A. et al. The impact of skin care products on skin chemistry and microbiome dynamics. *BMC Biol.* **17**, 47 (2019).
144. Costello, E. K. et al. Bacterial community variation in human body habitats across space and time. *Science* **326**, 1694–1697 (2009).
- This study demonstrates the important variability between body habitats and between individuals across the same body habitat.**
145. Kolodziejczyk, A. A., Zheng, D. & Elinav, E. Diet-microbiota interactions and personalized nutrition. *Nat. Rev. Microbiol.* **17**, 742–753 (2019).
146. Zaramela, L. S. et al. Gut bacteria responding to dietary change encode sialidases that exhibit preference for red meat-associated carbohydrates. *Nat. Microbiol.* **4**, 2082–2089 (2019).
147. Zmora, N., Suez, J. & Elinav, E. You are what you eat: diet, health and the gut microbiota. *Nat. Rev. Gastroenterol. Hepatol.* **16**, 35–56 (2019).
148. Etemadi, A. et al. Mortality from different causes associated with meat, heme iron, nitrates, and nitrites in the NIH-AARP Diet and Health Study: population based cohort study. *BMJ* **357**, j1957 (2017).
149. Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat. Med.* **19**, 576–585 (2013).
150. Gilbert, J. A. et al. Current understanding of the human microbiome. *Nat. Med.* **24**, 392–400 (2018).
151. Durack, J. & Lynch, S. V. The gut microbiome: relationships with disease and opportunities for therapy. *J. Exp. Med.* **216**, 20–40 (2019).
152. Lai, Y. et al. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. *Nat. Med.* **15**, 1377–1382 (2009).

153. Chng, K. R. et al. Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. *Nat. Microbiol.* **1**, 16106 (2016).
154. Li, H. et al. Skin commensal *Malassezia globosa* secreted protease attenuates *Staphylococcus aureus* biofilm formation. *J. Invest. Dermatol.* **138**, 1137–1145 (2018).
155. Shirliff, M. E., Peters, B. M. & Jabra-Rizk, M. A. Cross-kingdom interactions: *Candida albicans* and bacteria. *FEMS Microbiol. Lett.* **299**, 1–8 (2009).
156. Santus, W., Devlin, J. R. & Behnsen, J. Crossing kingdoms: how the mycobiota and fungal-bacterial interactions impact host health and disease. *Infect. Immun.* **89**, e00648–20 (2021).
157. Taur, Y. et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. *Sci. Transl. Med.* **10**, eaap9489 (2018).
This study shows that autologous faecal microbiota transplantation helps to restore the microbiota of patients who underwent antibiotic treatment.
158. van Nood, E., Dijkgraaf, M. G. W. & Keller, J. J. Duodenal infusion of feces for recurrent *Clostridium difficile*. *N. Engl. J. Med.* **368**, 2145 (2013).
159. Tariq, R., Pardi, D. S., Bartlett, M. G. & Khanna, S. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent *Clostridium difficile* infection: a systematic review and meta-analysis. *Clin. Infect. Dis.* **68**, 1351–1358 (2019).
160. Panigrahi, P. et al. Corrigendum: a randomized synbiotic trial to prevent sepsis among infants in rural India. *Nature* **553**, 238 (2018).
161. Halkjaer, S. I. et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. *Gut* **67**, 2107–2115 (2018).
162. Korpela, K. et al. Maternal fecal microbiota transplantation in cesarean-born infants rapidly restores normal gut microbial development: a proof-of-concept study. *Cell* **183**, 324–334.e5 (2020).
163. Morton, J. T. et al. Learning representations of microbe–metabolite interactions. *Nat. Methods* **16**, 1306–1314 (2019).
164. Kehe, J. et al. Positive interactions are common among culturable bacteria. *Sci. Adv.* **7**, eabi7159 (2021).
165. Strandwitz, P. et al. GABA-modulating bacteria of the human gut microbiota. *Nat. Microbiol.* **4**, 396–403 (2019).
166. Rubin, B. E. et al. Species- and site-specific genome editing in complex bacterial communities. *Nat. Microbiol.* **7**, 34–47 (2022).
167. Zmora, N. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. *Cell* **174**, 1388–1405.e21 (2018).
168. Zeevi, D. et al. Personalized nutrition by prediction of glycemic responses. *Cell* **163**, 1079–1094 (2015).
169. Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant *Acinetobacter baumannii* infection. *Antimicrob. Agents Chemother.* **61**, e00954–17 (2017).
170. Mu, A. et al. Effects on the microbiome during treatment of a staphylococcal device infection. Preprint at *Research Square* <https://doi.org/10.21203/rs.3.rs-969336/v1> (2021).
171. Claesson, M. J. et al. Gut microbiota composition correlates with diet and health in the elderly. *Nature* **488**, 178–184 (2012).
This study reports microbial community alterations between older individuals (aged 65 years and older) dependent on whether they live in the company of others or alone, the latter of which was correlated to worse outcomes (that is, frailty and co-morbidity).
172. Wu, L. et al. A cross-sectional study of compositional and functional profiles of gut microbiota in Sardinian centenarians. *mSystems* **4**, e00325–19 (2019).
173. Kong, F. et al. Gut microbiota signatures of longevity. *Curr. Biol.* **26**, R832–R833 (2016).
174. Claesson, M. J. et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc. Natl Acad. Sci. USA* **108** (Suppl. 1), 4586–4591 (2011).
175. O'Toole, P. W. & Jeffery, I. B. Gut microbiota and aging. *Science* **350**, 1214–1215 (2015).
176. Shibagaki, N. et al. Aging-related changes in the diversity of women's skin microbiomes associated with oral bacteria. *Sci. Rep.* **7**, 10567 (2017).
177. Liu, S., Wang, Y., Zhao, L., Sun, X. & Feng, Q. Microbiome succession with increasing age in three oral sites. *Aging* **12**, 7874–7907 (2020).
178. Schwartz, J. L. et al. Old age and other factors associated with salivary microbiome variation. *BMC Oral. Health* **21**, 490 (2021).
179. Strati, F. et al. Age and gender affect the composition of fungal population of the human gastrointestinal tract. *Front. Microbiol.* **7**, 01227 (2016).
180. Wu, L. et al. Age-related variation of bacterial and fungal communities in different body habitats across the young, elderly, and centenarians in Sardinia. *mSphere* **5**, e00558–19 (2020).
181. Nagpal, R. et al. Gut microbiome and aging: physiological and mechanistic insights. *Nutr. Healthy Aging* **4**, 267–285 (2018).
182. Wilmanski, T. et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. *Nat. Metab.* **3**, 274–286 (2021).
183. Sato, Y. et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. *Nature* **599**, 458–464 (2021).
This study finds that centenarians often had high abundances of microorganisms that produced unique secondary bile acids, namely various isoforms of lithocholic acid.
184. Gill-King, H. in *Forensic Taphonomy: the Postmortem Fate of Human Remains* 93–108 (CRC, 1997).
185. Janaway, R. C., Percival, S. L. & Wilson, A. S. in *Microbiology and Aging* (ed. Percival, S. L.) 313–334 (Humana, 2009).
186. Forbes, S. L., Perrault, K. A. & Comstock, J. L. in *Taphonomy of Human Remains: Forensic Analysis of the Dead and the Depositional Environment* (eds Schotsmans, E. M. J., Márquez-Grant, N. & Forbes, S. L.) 26–38 (Wiley, 2017).
187. Heimesaat, M. M. et al. Comprehensive postmortem analyses of intestinal microbiota changes and bacterial translocation in human flora associated mice. *PLoS ONE* **7**, e40758 (2012).
188. Parkinson, R. A. et al. in *Criminal and Environmental Forensics* (eds Ritz, K., Dawson, L. & Miller, D.) 379–394 (Springer, 2009).
189. Metcalf, J. L. et al. Microbial community assembly and metabolic function during mammalian corpse decomposition. *Science* **351**, 158–162 (2016).
This study finds that the time since death was predictable through the microbial community composition independent of the soil type and season.
190. DeBruyn, J. M. & Hauther, K. A. Postmortem succession of gut microbial communities in deceased human subjects. *PeerJ* **5**, e3437 (2017).
191. Pechal, J. L., Schmidt, C. J., Jordan, H. R. & Benbow, M. E. A large-scale survey of the postmortem human microbiome, and its potential to provide insight into the living health condition. *Sci. Rep.* **8**, 5724 (2018).
192. Kodama, W. A. et al. Trace evidence potential in postmortem skin microbiomes: from death scene to morgue. *J. Forensic Sci.* **64**, 791–798 (2019).
193. Hauther, K. A., Cabaugh, K. L., Jantz, L. M., Sparer, T. E. & DeBruyn, J. M. Estimating time since death from postmortem human gut microbial communities. *J. Forensic Sci.* **60**, 1234–1240 (2015).
194. Burcham, Z. M. et al. Fluorescently labeled bacteria provide insight on post-mortem microbial transmigration. *Forensic Sci. Int.* **264**, 63–69 (2016).
195. Burcham, Z. M. et al. Bacterial community succession, transmigration, and differential gene transcription in a controlled vertebrate decomposition model. *Front. Microbiol.* **10**, 745 (2019).
196. Balzan, S., de Almeida Quadros, C., de Cleva, R., Zilberstein, B. & Ceconello, I. Bacterial translocation: overview of mechanisms and clinical impact. *J. Gastroenterol. Hepatol.* **22**, 464–471 (2007).
197. Metcalf, J. L. et al. A microbial clock provides an accurate estimate of the postmortem interval in a mouse model system. *eLife* **2**, e01104 (2013).
198. Hyde, E. R., Haarmann, D. P., Petrosino, J. F., Lynne, A. M. & Buchell, S. R. Initial insights into bacterial succession during human decomposition. *Int. J. Leg. Med.* **129**, 661–671 (2015).
199. Javan, G. T., Finley, S. J., Smith, T., Miller, J. & Wilkinson, J. E. Cadaver thanatobiome signatures: the ubiquitous nature of *Clostridium* species in human decomposition. *Front. Microbiol.* **8**, 2096 (2017).
200. Johnson, H. R. et al. A machine learning approach for using the postmortem skin microbiome to estimate the postmortem interval. *PLoS ONE* **11**, e0167370 (2016).
201. Belk, A. et al. Microbiome data accurately predicts the postmortem interval using random forest regression models. *Genes* **9**, 104 (2018).
202. Metcalf, J. L. Estimating the postmortem interval using microbes: knowledge gaps and a path to technology adoption. *Forensic Sci. Int. Genet.* **38**, 211–218 (2019).
203. Deel, H. et al. A pilot study of microbial succession in human rib skeletal remains during terrestrial decomposition. *mSphere* **6**, e0045521 (2021).
204. Metcalf, J. L. et al. Microbiome tools for forensic science. *Trends Biotechnol.* **35**, 814–823 (2017).
205. Nguyen, T. T., Hathaway, H., Kosciolk, T., Knight, R. & Jeste, D. V. Gut microbiome in serious mental illnesses: a systematic review and critical evaluation. *Schizophr. Res.* **234**, 24–40 (2021).
206. Jeste, D. V., Koh, S. & Pender, V. B. Perspective: social determinants of mental health for the new decade of healthy aging. *Am. J. Geriatr. Psychiatry* **30**, 733–736 (2022).
207. Matijašić, M. et al. Gut microbiota beyond bacteria–mycobiome, virome, archaeome, and eukaryotic parasites in IBD. *Int. J. Mol. Sci.* **21**, 2668 (2020).
208. Morton, J. T. et al. Establishing microbial composition measurement standards with reference frames. *Nat. Commun.* **10**, 2719 (2019).
209. Gerber, G. K. The dynamic microbiome. *FEBS Lett.* **588**, 4131–4139 (2014).
210. Zarrinpar, A., Chaix, A., Yooseph, S. & Panda, S. Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. *Cell Metab.* **20**, 1006–1017 (2014).
211. Vázquez-Baeza, Y. et al. Guiding longitudinal sampling in IBD cohorts. *Gut* **67**, 1743–1745 (2018).
212. Kane, P. B., Bittlinger, M. & Kimmelman, J. Individualized therapy trials: navigating patient care, research goals and ethics. *Nat. Med.* **27**, 1679–1686 (2021).
213. Huang, S. et al. Human skin, oral, and gut microbiomes predict chronological age. *mSystems* **5**, e00630–19 (2020).
214. Thompson, L. R. et al. A communal catalogue reveals Earth's multiscale microbial diversity. *Nature* **551**, 457–463 (2017).
215. Franzosa, E. A. et al. Identifying personal microbiomes using metagenomic codes. *Proc. Nat. Acad. Sci. USA* **112**, E2930–E2938 (2015).
216. Vangay, P. et al. Microbiome metadata standards: report of the national microbiome data collaborative's workshop and follow-on activities. *mSystems* **6**, e01194–20 (2021).

Acknowledgements

This work was supported by the US National Institute of Justice under award number 2016-DN-BX-0194 (to R.K. and J.L.M.) and the US National Institutes of Health under award number U19AG063744 Project 1: Changes in Gut Microbiome (to R.K.). A.H.D. is supported by the Stein Institute for Research on Aging, the Natasha Josefowitz Predoctoral Fellowship and the Reiter Endowed Fellowship.

Author contributions

A.H.D. and C.M. researched data for the article. All authors discussed the content, wrote the article, and reviewed and edited the manuscript before submission.

Competing interests

The authors declare no competing interests.

Peer review information

Nature Reviews Microbiology thanks Christopher Stewart and the other, anonymous, reviewers for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at <https://doi.org/10.1038/s41579-022-00768-z>.

© Springer Nature Limited 2022